The role of nuclear medicine in differentiated thyroid cancer
First Online: 20 July 2012 Received: 14 May 2012 Accepted: 21 June 2012 DOI:
10.1007/s10354-012-0129-5 Cite this article as: Kohlfürst, S. Wien Med Wochenschr (2012) 162: 407. doi:10.1007/s10354-012-0129-5 Abstract
In differentiated thyroid cancer (DTC) nuclear medicine is able to cover the spectrum from diagnosis and treatment to follow up keeping patient’s management in one institution. Nowadays, DTC is often diagnosed per chance, presenting as small indolent nodule diagnosed on routinely performed ultrasound. Ultrasound and ultrasonography-guided fine-needle aspiration biopsy together with scintigraphy are probably the most adequate tools for diagnosis. After thyroidectomy, treatment with iodine-131 is routinely performed in a nuclear medicine therapy institution as a standard procedure in most of the cases with regard to histology. In case of iodine positive metastases, repeated therapies can be performed in order to reduce tumour burden. In the follow up of DTC thyroglobulin (tumour marker), ultrasound and diagnostic whole body scan are established procedures. With the development of SPECT/CT and PET/CT (
18F-FDG, 68Ga-somatostatin receptor) combining functional and anatomic imaging the nuclear medicine spectrum has further increased. Keywords Diagnosis of differentiated thyroid cancer Therapy of differentiated thyroid cancer Follow up of differentiated thyroid cancer References
Gomez-Segovia I, Gallowitsch HJ, Kresnik E, et al. Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984–2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990: population based age stratified analysis on thyroid carcinoma incidence. Thyroid. 2004;14(4):277–86.
Lind P, Kumnig G, Heinisch M, et al. Iodine supplementation in Austria: methods and results. Thyroid. 2002;12:903–7.
Colonna M, Guizard AV, Schvartz C, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000). Eur J Cancer. 2007;43(5):891–900.
Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2010;16 Suppl 1:1–43.
Hambly NM, Gonen M, Gerst SR, et al. Implementation of evidence-based guidelines for thyroid nodule biopsy: a model for establishment of practice standards. AJR AM J Roentgenol. 2011;196(3):655–60.
Chan BK, Desser TS, Mc Dougall IR, et al. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med. 2003;22:1083–90.
Mikosch P, Gallowitsch HJ, Kresnik E, et al. Präoperative Dignitätsabklärung von Schilddrüsenknoten im Strumaendemiegebiet: Möglichkeiten und Limitationen. Wien Med Wochenschr. 2000;150:278–287.
Wong KT, Ahuja AT. Ultrasound of thyroid cancer. Cancer Imaging. 2005;5:157–66.
De Nicola H, Szejnfeld J, Logullo AF, et al. Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasm. J Ultrasoun Med. 2005;24(7):897–904.
Bianek-Bodzak A, Zaleski K, Studniarek M, et al. Color Doppler sonography in malignancy of thyroid nodules. J Ultrasoun Med. 2003;22:758.
Rago T, Santini F, Scutari M. Elastography: new developments in ultrasound for predecting malignancy in thyroid nodules. J Clin Endocrinol Metab. 2007;92:2917–22.
Rago T, Scutari M, Scartini F, et al. Real-time elastosonography: useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or non diagnostic cytology. J Clin Endocrinol Metab. 2010;95(12):5274–80.
Rorive S, D’Hene N, Fossion C, et al. Ultrasound-guided fine-needle aspiration of thyroid nodules: stratification of malignancy risk using follicular proliferation grading, clinical and ultrasonographic features. Eur J Endocrinol. 2010;162:1107–15.
Mikosch P, Gallowitsch HJ, Kresnik E, et al. Value of ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in an endemic goitre area. Eur J Nuc Med. 2000;27(1):62–9.
Carmeci C, Jeffrey RB, Mc Dougall IR, et al. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid. 1998,8(4):283–289.
Kresnik E, Gallowitsch HJ, Mikosch P, et al. Scintigraphic and ultrasonographic appearance in different tumor stages of thyroid carcinoma. Acta Med Austraca. 2000;27(1):32–5.
Kusic Z, Becker DV, Saenger EL, et al. Comparison of technetium-99m and iodine-123 imaging of thyroid nodules: correlation with pathologic findings. J Nucl Med. 1990;31(4):393–9.
Beierwalters WH. Comparison of technetium-99m and iodine-123 nodules: correlation with pathologic findings. J Nucl Med. 1990;31(4):400–2.
Kresnik E, Gallowitsch HJ, Mikosch P, et al. Evaluation of thyroid nodules with Tc-99m tetrofosmin dual phase scintigraphy. Eur J Nucl Med. 1997;24:716–21.
Lind P. Multi-tracer imaging of thyroid: is there a role in the preoperative assessment of nodular goiter? Eur J Nucl Med. 1999;26:795–7.
Kim BS, Kim SJ, Kim IJ, et al. Factors associated with positive F-18 Fluorodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma. Thyroid. 2012 Mar 5 Epub ahead of print.
Deandreis D, Al Ghuzlan A, Auperin A, et al. Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid. 2012;22(2):165–72.
Joensuu H, Ahonen A, Klemi PJ. 18F-fluorodeoxyglucose imaging in the preoperative diagnosis of thyroid malignancy. Eur J Nucl Med. 1988;13:502–506.
Verburg FA, Stockel MP, Düren C, et al. No survival difference after successful I131 ablation between patients with initially low risk and high risk differentiated thyroid cancer. Nucl Med Mol Imaging. 2010;37(2):276-83.
Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.
Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371–7.
Coopers DS, Doberty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42.
Luster M, Clarke SE, Dietlein M; et al. Guidelines on radioiodine treatment of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59.
Pacini F, Castagna MG, Brilli L, et al. Differentiated thyroid cancer: ESMO Clinical recommendations for diagnosis, treatment and follow up. Ann Oncol 2010;21 Suppl 5:214–9.
Hackshaw A, Hasmer C, Mallick U, et al. 131 I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab. 2007;92:28–38.
Pilli T, Brianzoni E, Capocetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administration doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. JCEM. 2007;92(9):3542.
Hermann M, Tonninger K, Kober F. Minimal invasive follicular thyroid carcinoma. Not always total thyroidectomy. Chirurg. 2010;81:627–635.
Thompson LD, Wieneke JA, Paal E, et al. A clinopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer. 2001;91(3):505-24.
Pacini F, Schlumberger M, Dralle H, et al. European thyroid cancer taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.
Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10:573–7.
Kohlfuerst S, Igerc I, Lobnig M, et al. Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging. 2009;36:886–893.
Schmidt D, Szikszai A, Linke R, et al. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50:18–23.
Grewal RK, Tuttle RM, Fox J, et al. The effect of posttherapy 131 SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010;51(9):1361–7.
Van Herle AJ, Uller RP. Elevated thyroglobulin: a marker of metastases in differentiated thyroid carcinoma. J Clin Invest. 1975;56:272–6.
Cherk MH, Francis P, Topliss DJ, et al. Incidence and implications of negative serum thyroglobulin but positive I‐131 whole body scans in patients with well differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal. Clin Endocrinol (Oxf) 2012;76(5):734–40
Lind P, Kohlfürst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med. 2006;36(3):194–205.
Pacini F. Follow up of differentiated thyroid cancer. Eur J Nucl Med. 2002;29 Suppl 2:492–496.
Haber RS. Role of ultrasonography in the diagnosis and management of thyroid cancer. Endocr Pract. 2000;6:396–400.
Rosario PW, de Faria S, Bicalho L, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med. 2005;24(10):1385–9.
Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668–3673.
Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89:3402–3407.
Lubin E, Mechlis-Frish S, Zatz S et al. Serum thyroglobulin and iodine-131 whole body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med. 1994;35(2):257–262.
De Meer SG, Vriens MR, Zelissen PM, et al. The role of routine-diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer.J Nucl Med. 2011;52(1):56–9.
Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80(5):1488–92.
Lind P. Should high hTg levels in the absence of iodine uptake be treated. Eur J Nucl Med. 2003;30:157–160.
Barwick T, Murray I, Megadmi H et al. Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010;162(6):1131–9.
Spanu A, Solinas ME, Chessa F, et al. 131 I SPECT/CT in the follow up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50(2):184–90.
Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging. 2007;34(4):487–95.
Bannas P, Derlin T, Groth M, et al. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Ann Nucl Med. 2012;26(1):77–5.
Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48(2):221–6.
Giovanella L, Ceriani L, De Palma D, et al. Relationship between serum thyroglobulin and (18) FDG PET/CT in (131) I‐negative differentiated thyroid carcinomas. Head Neck 2012;34(5):626–31.
Leboulleux S, Schroeder PR, Busaidy NL. Assessment of the incremental value of recombinant TSH stimulation before FDG PET/CT imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009;94:1310–1316.
Petrich T, Börner AR, Otho D. Influence of rhTSH on ((18)F) fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2002;29(5):641–7.
Jentzen W, Freudenberg L, Bockisch A, et al. Quantitative imaging of (124)I with PET/CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging. 2011;55(1):21–43.
Freudenberg LS, Jentzen W, Stahl A, et al. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 1:S48–56.
Middendorp M, Selkinski I, Happel C, et al. Comparison of positron emission tomography with 18F FDG and 68 Ga DOTATOC in recurrent differentiated thyroid cancer. Preliminary data. Q J Nucl med Mol Imaging. 2010;54(1):76–83.
Gabriel M, Andergassen U, Putzer D, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging. 2010;54(1):92–9.
PubMed Copyright information
© Springer-Verlag Wien 2012